BALTIMORE - December 8, 2022 - (Newswire.com)

For the sixth time, Protenus, the nation's leading healthcare compliance analytics technology platform provider, has been selected by The Tech Tribune as one of the 10 Best Tech Startups in Baltimore.

The annual award and publication by The Tech Tribune staff considers several factors, including but not limited to revenue potential, leadership team, brand/product traction, and competitive landscape. All companies also must be independent (unacquired), privately owned, no older than 10 years, and have received at least one round of funding in order to qualify.

"At Protenus, our AI and advanced analytics help healthcare organizations proactively identify and work to prevent patient privacy violations and clinical drug diversion. We're committed to innovation, risk reduction, and supporting our community of employees and customers; I think that shines through in everything we do and is a major reason we're receiving this recognition for the sixth year," said Nick Culbertson, Protenus CEO and Co-Founder. "Protenus was founded in Baltimore and though we now have employees stretching from coast to coast, our headquarters remain in this great city." 

The complete list of this year's winners is available here.

About Protenus

Protenus harnesses the power of AI to provide healthcare organizations with scalable risk-reduction solutions that drive the safest patient outcomes while protecting the reputation of the organizations. We are committed to innovation, determined to reduce risk, and focused on supporting our community of employees, customers, and ultimately, patients. Empowering healthcare to eliminate risk is at the heart of all we do.

Founded in 2014, Protenus is a three-time winner of Forbes' America's Best Startup Employers, is a Great Place to Work®-Certified company, and was named one of 2021 CBInsights Digital Health 150, one of The Best Places to Work in Healthcare by Modern Healthcare, and one of the Best Places to Work in Baltimore by the Baltimore Business Journal and the Baltimore Sun. Learn more at Protenus.com and follow us on Twitter @Protenus

Contact Information:
Amanda Rogers
Marketing Content Writer
[email protected]


Press Release Service by Newswire.com

Original Source: Protenus Recognized as One of the Best Tech Startups in Baltimore for the 6th Year

As the top general dentists in Orland Park, Inspire Dental Wellness offers a variety of services that keep every family member covered no matter what their dental needs are.

ORLAND PARK, Ill. - December 8, 2022 - (Newswire.com)

The team of Orland Park dentists at Inspire Dental Wellness ensures that every family member receives the proper oral care they need, even those without insurance coverage. The clinic specializes in oral health care for all members of the family, with personalized treatment for patients of all ages.

The two talented dentists at Inspire Dental Wellness provide an all-encompassing range of services. Dr. Erica Zolnierczyk specializes in both general and cosmetic dentistry, with a focus on facial and airway development, preventative care, and more. She takes time when consulting patients to understand their concerns and to develop a plan with their goals and healthcare needs in mind.

Dr. Badia Zahdan is a cosmetic and family dentist who works with all ages, including young children and babies. Along with her many specializations, such as routine check-ups, cleanings, and fillings, Dr. Zahdan helps with infants' oral care, as seen in Inspire Dental Wellness's Mini Sproutz™ Baby Oral Care Development Program.

Adult patients can benefit from a wide range of dentistry services, whether it's a standard check-up, a simple cleaning, or even a complete smile makeover, including veneers and implants. They also offer orthodontic services such as braces to promote optimal oral health.

Since investment in the overall health and well-being of all patients is the top priority at Inspire Dental Wellness, the team believes that financial considerations and insurance should never be an obstacle to receiving quality dental care. For this reason, the clinic offers various in-house membership plans that include services such as cleanings, check-ups, x-rays, and emergency exams as needed. They also offer an array of dental financing options to help those without dental insurance. For those who do have insurance, they accept most dental plans.

Readers interested in receiving comprehensive oral care for all family members can contact Inspire Dental Wellness at (708) 460-6699 or visit their website to schedule an appointment.

About Inspire Dental Wellness

Inspire Dental Wellness is a premier dental clinic located in Orland Park, Illinois, offering a wide range of routine, preventative, and cosmetic dental procedures. Their primary goal is to provide the highest level of care while simultaneously prioritizing the comfort and happiness of their patients.

For more information, please visit www.inspiredentalwellness.com.

Contact:

Inspire Dental Wellness

(708) 460-6699

Contact Information:
Paul Zolnierczyk
Co-Owner
[email protected]
708-979-9284


Press Release Service by Newswire.com

Original Source: Inspire Dental Wellness Provides Comprehensive Dental Care for All Members of the Family

Federal Court to weigh controversial bill that PIC argues is an unlawful targeting of scientific dissent as 'misinformation'

NEWPORT BEACH, Calif. - December 7, 2022 - (Newswire.com)

Physicians for Informed Consent (PIC), an educational nonprofit organization focused on science and statistics, has filed a First Amendment free speech lawsuit (2:22-cv-02147) in the United States District Court for the Eastern District of California, and request for preliminary injunction, against the State of California and Osteopathic Medical Board of California in order to protect the free speech of all physicians in California.

The Plaintiffs are PIC and one of its founding members, physician LeTrinh Hoang, D.O., together with Children's Health Defense, California Chapter. The legal team managing the case are Rick Jaffe, Robert F. Kennedy Jr., and Mary Holland.

The lawsuit argues that the State has weaponized the vague phrase "misinformation," thereby unconstitutionally targeting physicians who publicly disagree with the government's public health edicts on COVID-19.

Expert cardiologist and PIC member Sanjay Verma, M.D., has been tracking and cataloging CDC errors in real time. For the case, he has provided what he calls "a detailed declaration exposing the government's scientific errors and the constitutional dangers of censoring dissent":

"To demonstrate these points of vagueness and the general unsuitability of using 'contemporary scientific consensus' as a disciplinary criterion, I have prepared a detailed overview of public health response to the pandemic broken down into categories such as Masks and Vaccines (transmission, safety, efficacy of natural immunity). I have also included evidence of what [I testify] would be considered misinformation promulgated by the CDC as well as its withholding of information which led to the then 'contemporary scientific consensus' eventually being proven wrong."

PIC President Shira Miller, M.D., was active in opposing AB 2098 while it was navigating the California legislative process, and has led the effort to bring the instant lawsuit. Opposing the bill, she wrote, "Public health is not achieved, and scientific knowledge does not progress, by censoring dissenting physicians and surgeons or anyone else. AB 2098 is anti-doctor, anti-public health, anti-science, and anti-free speech."

The scheduled hearing on PIC's motion for preliminary injunction is Jan. 17, 2023. PIC has requested the District Court issue a preliminary injunction that "AB 2098 is unconstitutional on its face." The Complaint also requests the Court "issue a declaratory judgement that PIC and CHD patient members have a privacy right in their prescriptions for any off-label FDA approved medication" such as ivermectin and hydroxychloroquine. 

Physicians for Informed Consent is a 501(c)(3) tax-exempt nonprofit educational organization supported only by the generous contributions of our members and supporters. Click here to make a contribution.

Contact Information:
Greg Glaser
General Counsel
[email protected]
925-642-6651


Press Release Service by Newswire.com

Original Source: Physicians for Informed Consent Sues State of California, Argues That Doctor Censorship Bill AB 2098 Violates the U.S. Constitution

SUNNYVALE, Calif. - December 7, 2022 - (Newswire.com)

Riboscience, LLC, a private clinical-stage biotechnology company leveraging a proprietary library of nucleoside and non-nucleoside analogues to rationally design drug candidates that are highly efficacious and highly selective for essential targets in the virology and oncology spaces, today announced the publication of two abstracts that will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2022, taking place virtually and on-site in Geneva, Switzerland, from Dec. 7-9, 2022.

Abstract #195TiP outlines the trial design for the Phase 1 clinical evaluation of orally administered RBS2418, a potent and selective ENPP1 inhibitor.  ENPP1 inhibition results in the protection of immune-activating cGAMP and ATP from hydrolysis in the TME and in the reduced production of immune-suppressive adenosine. The ongoing study is a Phase 1a/b, open-label, non-randomized study in patients (pts) (≥18 years) with advanced, unresectable, recurrent or metastatic solid tumors, who have progressed on, or are ineligible for standard therapies. The study begins with dose-escalation where in a 3+3 fashion, pts will receive in one cohort RBS2418 starting at 100mg bid as monotherapy and in a second cohort RBS2418 in combination with Pembrolizumab (200 mg IV q3w). The study will enroll up to 64 pts at 10 sites in the U.S. The primary objectives of the study are safety, tolerability, ENPP1 inhibition and cGAMP protection of RBS2418 as monotherapy and in the combination setting. Immune biomarkers predictive of anti-tumor responses will be explored as well as translational analyses will be done to explore the depth and breadth of immune activation both in tumor tissue and blood. This study is being funded by Riboscience, LLC. 

Abstract#169P summarizes the PK, PD and immunomodulatory profile of RBS2418, which is also the first-in-human experience with an ENPP1 inhibitor. This was an expanded access study in a patient with advanced adrenal cancer, who had previously progressed on a treatment with pembrolizumab and cabozantinib. The results showed that weekly intra-patient escalation of doses from 100 mg BID to 400 mg BID in combination with pembrolizumab was safe, well tolerated with no DLTs. RBS2418 PK data showed oral bioavailability with plasma levels leading to complete serum ENPP1 inhibition at all time points already at the 100 mg starting dose level. The treatment induced increases in peripheral cDCs, proliferation of CD4 and CD8 T cells and hyperexpansion of TCR clonotypes in peripheral blood as well as upregulation of T cell cytotoxic granule protein gene expression, consistent with a treatment-induced immune activation from a baseline cold tumor phenotype. These results support further clinical development of this novel first-in-class immunotherapy agent in the on-going Phase1a/b clinical trial described above (NCT05270213).

 

 

 

Abstract Title	Poster	Presentation Date/Time (CET)/Location
A First-In-Human, Phase 1 a/b Dose Escalation and Expansion Study to Evaluate RBS2418 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Unresectable, Recurrent or Metastatic Tumors (NCT05270213)	#195TiP	December 8/12:30 p.m./ Foyer ABC Palexpo exhibition center, Geneva
Immunomodulatory effects of RBS2418, an oral ENPP1 inhibitor in combination with pembrolizumab in checkpoint-refractory metastatic adrenal cancer	#169P	December 8/12:30 p.m./ Foyer ABC Palexpo exhibition center, Geneva

About Riboscience, LLC.
Riboscience applies specialized chemistry and biology to create novel treatments for human diseases. We particularly focus on building ribose-based molecules, and we use structure-guided design to generate highly selective and efficacious drug candidates.

Nucleoside analogs are examples of ribose-based molecules that have become important drugs for the treatment of a number of viral diseases and cancers. The Riboscience library of nucleoside and non-nucleoside molecules is rationally designed to deliver drug candidates that are highly efficacious and highly selective for essential targets in the virology and oncology spaces.

About RBS2418.

RBS2418 is a nucleoside-derived small molecule that has been optimized for potent (picomolar binding affinity) and selective binding to the active site of ENPP1. ENPP1 is the only enzyme known in humans to hydrolyze the immune-activating messenger molecule cGAMP that is generated in tumor cells in the context of replication errors, DNA damage and a variety of replication defects. ENPP1 also hydrolyzes ATP and contributes to the generation of increased immune-suppressive adenosine levels in the TME. ENPP1 upregulation is commonly observed in tumors and is associated with immune evasion, cold tumor phenotype, disease progression and non-response to checkpoint inhibitors. RBS2418 is the first clinical-stage ENPP1 inhibitor and is being investigated in a Phase 1a/b dose escalation and expansion study as monotherapy and in combination with Pembrolizumab. Refer to the clinicaltrials.gov overview for more information:  RBS2418 Evaluation in Subjects With Unresectable or Metastatic Tumors - Full Text View - ClinicalTrials.gov. For additional information, please visit https://www.Riboscience.com. 

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated," and "intend" or other similar terms or expressions that concern Riboscience expectations, strategy, plans or intentions. These forward-looking statements are based on Riboscience's current expectations and actual results could differ materially. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Riboscience, LLC does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Riboscience Contact:

Jill Jene, Ph.D., MBA

Chief Business Officer

[email protected]

Contact Information:
Jill Jene
CBO
[email protected]


Press Release Service by Newswire.com

Original Source: Riboscience ESMO I/O Presentations Highlight RBS2418 Phase 1 Study Design and the First Human Data From the Evaluation of an ENPP1 Inhibitor for Immune Activation